Increase in mortality rate following coprescription of cisapride and contraindicated drugs
Increase in mortality rate following coprescription of cisapride and contraindicated drugs
复制标题
DOI：
10.1345/aph.1h247
复制
发表时间：
2007-04-01
影响因子：
2.9
通讯作者：
Park, Byung-Joo
中科院分区：
文献类型：
--
作者：
Choi, Nam-Kyong;Hahn, Seokyung;Park, Byung-Joo
背景技术背景：没有流行病学研究，作为这篇文章，已经发表了关于使用西沙必利与禁忌药物及其与死亡率的关系在人口为基础的setting.OBJECTIVE：估计的患病率与禁忌药物的西沙必利的伴随使用，并评估这之间的关联和死亡率的风险mortality.METHODS：索赔数据来自韩国健康保险审查机构。研究人群包括2000年11月1日至2002年4月30日期间作为西沙必利新用户访问釜山市诊所或医院的85岁以下患者。西沙必利的共同处方定义为西沙必利与一种或多种禁忌药物使用相同处方。还使用了全国范围的死亡率数据。估计了共同描述的西沙比利的患病率，并通过率比（RR）评估了这与死亡风险之间的关联。估计RR使用考克斯的回归模型与时间依赖的协变量，调整年龄，性别，和comorbidity.RESULTS：共36865例患者的56012索赔是新规定西沙必利;其中，1175名患者（3.2%）同时使用至少一种禁忌药物，这表明调整后的死亡率RR为14.08（95% CI 7.41至26.76），近期使用者和1.33（95%CI 0.92至1.93）为过去的用户西沙必利。结论：尽管药物的商业营销停止，西沙必利仍在使用的诊所和医院在釜山。在许多情况下，西沙必利与禁忌药物合用，这与死亡率增加有关。
BACKGROUND: No epidemiologic study, as of this writing, has been published on the use of cisapride with contraindicated drugs and its relation to mortality rates in a population-based setting.OBJECTIVE: To estimate the prevalence of concomitant use of cisapride with contraindicated drugs and evaluate the association between this and the risk of mortality.METHODS: Claims data were obtained from the Health Insurance Review Agency of Korea. The study population consisted of patients younger than 85 years who visited clinics or hospitals in the city of Busan as new users of cisapride between November 1, 2000, and April 30, 2002. The coprescription of cisapride was defined as prescribing cisapride with one or more contraindicated drugs with the same prescription. Nationwide mortality data were also used. The prevalence of coprescribing cisapride was estimated and the association between this and the risk of mortality was assessed by rate ratios (RRs). The RRs were estimated using Cox's regression model with time-dependent covariate, adjusted for age, sex, and comorbidities.RESULTS: A total of 36 865 patients out of 56 012 claims were newly prescribed cisapride; of these, 1175 patients (3.2%) were concomitantly prescribed at least one contraindicated drug, which suggested adjusted mortality RRs of 14.08 (95% Cl 7.41 to 26.76) for recent users and 1.33 (95% Cl 0.92 to 1.93) for past users of cisapride.CONCLUSIONS: Despite the discontinuation of the drug's commercial marketing, cisapride was still in use in clinics and hospitals in Busan. In many cases, cisapride was co-prescribed with contraindicated drugs, which is associated with increased mortality rates.